- In February 2024, Teva Pharmaceuticals received U.S. FDA approval for its once-daily fixed-dose combination statin pill, which combines atorvastatin and ezetimibe. This innovative formulation is designed to simplify treatment for patients with high cholesterol by combining two lipid-lowering agents in a single tablet, improving adherence and therapeutic outcomes
- In October 2024, Amgen highlighted positive long-term real-world data for Repatha (evolocumab), a PCSK9 inhibitor often used alongside statins, at the American Heart Association Scientific Sessions. The data demonstrated sustained LDL-C reduction and cardiovascular benefit when used in combination with statins, reinforcing the value of combination therapies in high-risk patients
- In November 2023, Pfizer announced a new phase III clinical trial for its next-generation statin candidate aimed at patients with statin intolerance. This trial focuses on evaluating efficacy and safety among individuals who have experienced adverse effects from traditional statins, aiming to expand treatment options and reduce cardiovascular risks for underserved populations
- In June 2021, Centrient Pharmaceuticals announced the commencement of production at its newly built statins manufacturing facility. With the completion of this second dedicated unit at its Toansa site in India, the company has effectively doubled its statins production capacity
